JPWO2020206248A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020206248A5 JPWO2020206248A5 JP2021559084A JP2021559084A JPWO2020206248A5 JP WO2020206248 A5 JPWO2020206248 A5 JP WO2020206248A5 JP 2021559084 A JP2021559084 A JP 2021559084A JP 2021559084 A JP2021559084 A JP 2021559084A JP WO2020206248 A5 JPWO2020206248 A5 JP WO2020206248A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- nucleic acid
- sequence encoding
- seq
- hla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023085262A JP7516617B2 (ja) | 2019-04-03 | 2023-05-24 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| JP2024107199A JP2024153640A (ja) | 2019-04-03 | 2024-07-03 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962828794P | 2019-04-03 | 2019-04-03 | |
| US62/828,794 | 2019-04-03 | ||
| US201962843804P | 2019-05-06 | 2019-05-06 | |
| US62/843,804 | 2019-05-06 | ||
| US201962900126P | 2019-09-13 | 2019-09-13 | |
| US62/900,126 | 2019-09-13 | ||
| US201962930905P | 2019-11-05 | 2019-11-05 | |
| US62/930,905 | 2019-11-05 | ||
| US202063000774P | 2020-03-27 | 2020-03-27 | |
| US63/000,774 | 2020-03-27 | ||
| PCT/US2020/026571 WO2020206248A1 (en) | 2019-04-03 | 2020-04-03 | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023085262A Division JP7516617B2 (ja) | 2019-04-03 | 2023-05-24 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022526590A JP2022526590A (ja) | 2022-05-25 |
| JPWO2020206248A5 true JPWO2020206248A5 (https=) | 2023-04-10 |
| JP2022526590A5 JP2022526590A5 (https=) | 2023-04-10 |
| JP7286796B2 JP7286796B2 (ja) | 2023-06-05 |
Family
ID=70476389
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559084A Active JP7286796B2 (ja) | 2019-04-03 | 2020-04-03 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| JP2023085262A Active JP7516617B2 (ja) | 2019-04-03 | 2023-05-24 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| JP2024107199A Pending JP2024153640A (ja) | 2019-04-03 | 2024-07-03 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023085262A Active JP7516617B2 (ja) | 2019-04-03 | 2023-05-24 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
| JP2024107199A Pending JP2024153640A (ja) | 2019-04-03 | 2024-07-03 | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 |
Country Status (10)
| Country | Link |
|---|---|
| US (7) | US11008548B2 (https=) |
| EP (2) | EP3947682B1 (https=) |
| JP (3) | JP7286796B2 (https=) |
| KR (2) | KR20240122580A (https=) |
| CN (2) | CN116200342A (https=) |
| AU (1) | AU2020253538A1 (https=) |
| CA (1) | CA3135799A1 (https=) |
| IL (5) | IL299249B2 (https=) |
| MX (1) | MX2021012110A (https=) |
| WO (1) | WO2020206248A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925644T3 (es) * | 2016-10-04 | 2022-10-19 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células modificadas genéticamente |
| JP7821119B2 (ja) * | 2020-04-23 | 2026-02-26 | エーゼットセラピーズ， インコーポレイテッド | Ｈｌａクラスｉ ｍｈｃの細胞切除 |
| CN112725283B (zh) * | 2021-01-10 | 2023-01-06 | 武汉科技大学 | 靶向cd30和cd24的双靶点car-t细胞的构建方法及应用 |
| WO2022165111A1 (en) * | 2021-01-28 | 2022-08-04 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| IL304857A (en) | 2021-02-16 | 2023-10-01 | A2 Biotherapeutics Inc | Preparations and methods for treating HER2 POSITIVE cancer |
| CN117377756A (zh) * | 2021-03-05 | 2024-01-09 | 菲克特生物科学股份有限公司 | 工程化免疫细胞疗法 |
| WO2022192286A1 (en) * | 2021-03-09 | 2022-09-15 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins and rna interference |
| US20220315931A1 (en) * | 2021-03-26 | 2022-10-06 | A2 Biotherapeutics, Inc. | Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene |
| AU2022262648A1 (en) * | 2021-04-23 | 2023-11-09 | Baylor College Of Medicine | Car nkts expressing artificial micro rna-embedded shrna for downregulation of mhc class i & ii expression |
| WO2022272088A1 (en) * | 2021-06-24 | 2022-12-29 | Thunder Biotech, Inc. | Method of targeting cells and associated compositions |
| WO2023007373A1 (en) * | 2021-07-26 | 2023-02-02 | Crispr Therapeutics Ag | Methods for manufacturing genetically engineered car-t cells |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) * | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2023111913A1 (en) * | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption |
| GB202201927D0 (en) * | 2022-02-14 | 2022-03-30 | Kings College | Artificial microrna construct |
| EP4504221A4 (en) * | 2022-03-22 | 2026-02-25 | Celyntra Therapeutics Sa | Compositions and methods for generating cells with reduced immunogenicity |
| WO2023191957A1 (en) * | 2022-03-30 | 2023-10-05 | Mirimus, Inc. | Compositions and methods of generating novel amirna |
| EP4282963A1 (en) | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
| KR20250068649A (ko) * | 2022-09-13 | 2025-05-16 | 아스널 바이오사이언시스, 인크. | 공동 발현된 tgfbr shrna를 갖는 면역 세포 |
| JP2025535441A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| AU2023362748A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362746A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362749A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| WO2024149906A1 (en) * | 2023-01-13 | 2024-07-18 | Laverock Therapeutics Limited | Cell context-specific gene regulation using inhibitory rnas |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| GB202306619D0 (en) * | 2023-05-04 | 2023-06-21 | Antion Biosciences Sa | Cell |
| WO2025024849A1 (en) * | 2023-07-27 | 2025-01-30 | City Of Hope | Compositions and methods of making and using ipsc-derived car macrophages |
| WO2025102001A1 (en) * | 2023-11-10 | 2025-05-15 | Nchroma Bio, Inc. | Compositions and methods for multiplex epigenetic regulation |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| DE69534629D1 (de) | 1994-01-18 | 2005-12-29 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
| ATE524545T1 (de) | 1994-08-20 | 2011-09-15 | Gendaq Ltd | Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| EP1476547B1 (en) | 2002-01-23 | 2006-12-06 | The University of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| AU2006272634B2 (en) | 2005-07-26 | 2013-01-24 | Sangamo Therapeutics, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
| CA2891996A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| FR2931485B1 (fr) | 2008-05-23 | 2011-06-17 | Centre Nat Rech Scient | Vaccin antitumoral comprenant des cellules tumorales modifiees |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| HUE041436T2 (hu) | 2009-12-10 | 2019-05-28 | Univ Minnesota | Tal-effektor-közvetített DNS-módosítás |
| EP2694089B1 (en) | 2011-04-05 | 2024-06-05 | Cellectis | New tale-protein scaffolds and uses thereof |
| WO2012145384A1 (en) | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102437522B1 (ko) | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014117050A2 (en) | 2013-01-26 | 2014-07-31 | Mirimus, Inc. | Modified mirna as a scaffold for shrna |
| EP2971288A4 (en) | 2013-03-14 | 2016-12-07 | Elwha Llc | COMPOSITIONS, METHODS AND COMPUTER SYSTEMS FOR THE MANUFACTURE AND ADMINISTRATION OF MODIFIED T CELLS |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| AU2014248119B2 (en) | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
| CN115028735A (zh) | 2013-05-03 | 2022-09-09 | 俄亥俄州创新基金会 | Cs1-特异性嵌合抗原受体工程化的免疫效应细胞 |
| US10000746B2 (en) | 2013-05-31 | 2018-06-19 | Cellectis | LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX373460B (es) | 2014-03-11 | 2020-04-07 | Cellectis | Metodo para generar celulas t compatibles para el trasplante alogenico. |
| EP3206696A4 (en) * | 2014-10-14 | 2018-08-08 | Texas Tech University System | Multiplexed shrnas and uses thereof |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| BR112017011893A2 (pt) | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
| JP6949728B2 (ja) | 2015-05-29 | 2021-10-13 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞における阻害相互作用を調節するための組成物および方法 |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CN117070468A (zh) * | 2015-10-05 | 2023-11-17 | 精密生物科学公司 | 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞 |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| EA201891338A1 (ru) | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| EP3988655A3 (en) | 2015-12-23 | 2022-08-03 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| EP3512950A1 (en) * | 2016-09-14 | 2019-07-24 | Benitec Biopharma Limited | REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF |
| WO2018064594A2 (en) | 2016-09-29 | 2018-04-05 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
| ES2925644T3 (es) | 2016-10-04 | 2022-10-19 | Prec Biosciences Inc | Dominios coestimuladores para su uso en células modificadas genéticamente |
| EP4029943A1 (en) * | 2017-05-08 | 2022-07-20 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
| CA3071683A1 (en) | 2017-08-08 | 2019-02-14 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
-
2020
- 2020-04-03 JP JP2021559084A patent/JP7286796B2/ja active Active
- 2020-04-03 WO PCT/US2020/026571 patent/WO2020206248A1/en not_active Ceased
- 2020-04-03 EP EP20722776.0A patent/EP3947682B1/en active Active
- 2020-04-03 KR KR1020247025793A patent/KR20240122580A/ko active Pending
- 2020-04-03 AU AU2020253538A patent/AU2020253538A1/en active Pending
- 2020-04-03 EP EP23202634.4A patent/EP4332115A3/en active Pending
- 2020-04-03 CN CN202211544982.1A patent/CN116200342A/zh active Pending
- 2020-04-03 CA CA3135799A patent/CA3135799A1/en active Pending
- 2020-04-03 CN CN202080041015.6A patent/CN113993999B/zh active Active
- 2020-04-03 IL IL299249A patent/IL299249B2/en unknown
- 2020-04-03 KR KR1020217035888A patent/KR102691932B1/ko active Active
- 2020-04-03 IL IL326129A patent/IL326129A/en unknown
- 2020-04-03 MX MX2021012110A patent/MX2021012110A/es unknown
- 2020-04-03 IL IL316764A patent/IL316764A/en unknown
- 2020-06-22 US US16/908,030 patent/US11008548B2/en active Active
-
2021
- 2021-04-08 US US17/225,788 patent/US11186822B2/en active Active
- 2021-10-03 IL IL286896A patent/IL286896B2/en unknown
- 2021-10-26 US US17/511,022 patent/US11384335B2/en active Active
-
2022
- 2022-03-14 US US17/694,210 patent/US11453861B2/en active Active
- 2022-08-17 US US17/820,425 patent/US11851680B2/en active Active
-
2023
- 2023-05-24 JP JP2023085262A patent/JP7516617B2/ja active Active
- 2023-07-20 IL IL304624A patent/IL304624A/en unknown
- 2023-11-08 US US18/504,548 patent/US20240084252A1/en not_active Abandoned
-
2024
- 2024-07-03 JP JP2024107199A patent/JP2024153640A/ja active Pending
-
2025
- 2025-01-17 US US19/029,146 patent/US20250154460A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020206248A5 (https=) | ||
| IL299249B1 (en) | Genetically modified immune cells that include adapted shrna-microRNA (shrnamir) | |
| JP2024028986A5 (https=) | ||
| Dawson | A comparative assessment of the pig, mouse and human genomes | |
| JP5097714B2 (ja) | Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター | |
| JP2022137018A5 (https=) | ||
| JP2020074776A5 (https=) | ||
| JP2010519904A5 (https=) | ||
| JP2021519587A5 (https=) | ||
| JP2004532023A5 (https=) | ||
| KR20160102024A (ko) | 아데노바이러스 및 상응하는 플라스미드의 제조 방법 | |
| Ansardi et al. | Characterization of poliovirus replicons encoding carcinoembryonic antigen | |
| Gerald et al. | Measles virus haemagglutinin gene: cloning, complete nucleotide sequence analysis and expression in COS cells | |
| RU2002103870A (ru) | Человеческое моноклональное антитело против AILIM, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение | |
| Boudinot et al. | The glycoprotein of a fish rhabdovirus profiles the virus-specific T-cell repertoire in rainbow trout | |
| JP2005509420A5 (https=) | ||
| Anderson et al. | Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: amino acid substitutions affecting folding, transport and cleavage | |
| JPWO2019186274A5 (https=) | ||
| EP2573169B1 (en) | Cartilage-specific hif-2 transgenic mouse as an animal model for arthritis, and use thereof | |
| JPWO2022140587A5 (https=) | ||
| JPS61242582A (ja) | ヒトＴ細胞受容基のα鎖に特有なｃＤＮＡクロ−ン | |
| JP2022535458A (ja) | Ｂ型肝炎ウイルス特異的なｔ細胞応答 | |
| JP2004500117A5 (https=) | ||
| Rowe et al. | The kinetics of synthesis of early viral proteins in KB cells infected with wild-type and transformation-defective host-range mutants of human adenovirus type 5 | |
| JPWO2021226348A5 (https=) |